Interestingly, SOD1 G93A /RAG2 / and SOD1 G93A /CD4 / mice showed less activation of microglia at the end-stage compared to SOD1 G93A /RAG2 +/ or SOD1 G93A /CD4 +/ mice, even though their survival time was shorter
influences inflammatory response
Dubbed as IV therapy on the go, HINNAO now allows for a daily, cost-effective replacement dose, ensuring direct administration into the bloodstream, bypassing the stomach where other supplements may lose potency
Tripkovic, I., Ogorevc, M., Vukovic, D., Saraga-Babic, M
Available long-term data: Limited data beyond 12 weeks of continuous use No long-term safety concerns identified in available data Both peptides are based on naturally occurring compounds Theoretical profile favorable for extended use Long-term recommendations: Consider cycling on and off for very extended use Enhanced monitoring for protocols beyond 12 weeks Periodic assessment of continued need Documentation of long-term outcomes Theoretical long-term concerns: No major concerns identified Both peptides work with natural healing processes No evidence of tolerance or dependence No withdrawal effects on discontinuation Comparison to Alternative Treatments The safety profile compares favorably to alternatives
Glutathione levels can be increased through intravenous glutathione, multivitamin, and alpha-lipoic acid (with doses and frequency varying by individual)